Radiomics Biomarkers Correlate with CD8 Expression and Predict Immune Signatures in Melanoma Patients.
Biomarkers, Tumor
/ genetics
CD8-Positive T-Lymphocytes
/ metabolism
Humans
Immunotherapy
/ methods
Kaplan-Meier Estimate
Melanoma
/ diagnostic imaging
Mutation
Positron Emission Tomography Computed Tomography
/ methods
Prognosis
Proto-Oncogene Proteins B-raf
/ genetics
Proto-Oncogene Proteins p21(ras)
/ genetics
RNA-Seq
/ methods
Skin Neoplasms
/ diagnostic imaging
Tumor Microenvironment
/ genetics
Exome Sequencing
/ methods
Journal
Molecular cancer research : MCR
ISSN: 1557-3125
Titre abrégé: Mol Cancer Res
Pays: United States
ID NLM: 101150042
Informations de publication
Date de publication:
06 2021
06 2021
Historique:
received:
20
12
2020
revised:
18
02
2021
accepted:
24
03
2021
pubmed:
4
4
2021
medline:
27
1
2022
entrez:
3
4
2021
Statut:
ppublish
Résumé
Treatment for metastatic melanoma includes targeted and/or immunotherapy. Although many patients respond, only a subset has complete response. As late-stage patients often have multiple tumors in difficult access sites, non-invasive techniques are necessary for the development of predictive/prognostic biomarkers. PET/CT scans from 52 patients with stage III/IV melanoma were assessed and CT image parameters were evaluated as prognostic biomarkers. Analysis indicated patients with high standard deviation or high mean of positive pixels (MPP) had worse progression-free survival (
Identifiants
pubmed: 33811161
pii: 1541-7786.MCR-20-1038
doi: 10.1158/1541-7786.MCR-20-1038
doi:
Substances chimiques
Biomarkers, Tumor
0
Proto-Oncogene Proteins B-raf
EC 2.7.11.1
Proto-Oncogene Proteins p21(ras)
EC 3.6.5.2
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
950-956Informations de copyright
©2021 American Association for Cancer Research.
Références
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.
Ugurel S, Rohmel J, Ascierto PA, Flaherty KT, Grob JJ, Hauschild A, et al. Survival of patients with advanced metastatic melanoma: the impact of novel therapies-update 2017. Eur J Cancer. 2017;83:247–57.
Gide TN, Wilmott JS, Scolyer RA, Long GV. Primary and acquired resistance to immune checkpoint inhibitors in metastatic melanoma. Clin Cancer Res. 2018;24:1260–70.
Massi D, Rulli E, Cossa M, Valeri B, Rodolfo M, Merelli B, et al. The density and spatial tissue distribution of CD8(+) and CD163(+) immune cells predict response and outcome in melanoma patients receiving MAPK inhibitors. J Immunother Cancer. 2019;7:308.
Galon J, Bruni D. Approaches to treat immune hot, altered, and cold tumours with combination immunotherapies. Nat Rev Drug Discov. 2019;18:197–218.
Gajewski TF, Corrales L, Williams J, Horton B, Sivan A, Spranger S. Cancer immunotherapy targets based on understanding the T-cell–inflamed versus non-t cell-inflamed tumor microenvironment. Adv Exp Med Biol. 2017;1036:19–31.
Schroer-Gunther MA, Wolff RF, Westwood ME, Scheibler FJ, Schurmann C, Baumert BG, et al. F-18-fluoro-2-deoxyglucose positron emission tomography (PET) and PET/computed tomography imaging in primary staging of patients with malignant melanoma: a systematic review. Syst Rev. 2012;1:62.
Miles KA, Ganeshan B, Rodriguez-Justo M, Goh VJ, Ziauddin Z, Engledow A, et al. Multifunctional imaging signature for V-KI-RAS2 Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations in colorectal cancer. J Nucl Med. 2014;55:386–91.
Sun R, Limkin EJ, Vakalopoulou M, Dercle L, Champiat S, Han SR, et al. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti–PD-1 or anti–PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study. Lancet Oncol. 2018;19:1180–91.
Smith AD, Gray MR, del Campo SM, Shlapak D, Ganeshan B, Zhang X, et al. Predicting overall survival in patients with metastatic melanoma on antiangiogenic therapy and RECIST stable disease on initial posttherapy images using CT texture analysis. AJR Am J Roentgenol. 2015;205:W283–93.
Miles KA, Ganeshan B, Hayball MP. CT texture analysis using the filtration-histogram method: what do the measurements mean?. Cancer Imaging. 2013;13:400–6.
Aoude LG, Bonazzi VF, Brosda S, Patel K, Koufariotis LT, Oey H, et al. Pathogenic germline variants are associated with poor survival in stage III/IV melanoma patients. Scientific Reports. 2020;10:17687.
Song S, Nones K, Miller D, Harliwong I, Kassahn KS, Pinese M, et al. A tool to estimate tumor cellularity from genome-wide single-nucleotide polymorphism profiles. PLoS ONE. 2012;7:e45835.
Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2013;29:15–21.
DeLuca DS, Levin JZ, Sivachenko A, Fennell T, Nazaire MD, Williams C, et al. RNA-SeQC: RNA-seq metrics for quality control and process optimization. Bioinformatics. 2012;28:1530–2.
Li B, Dewey CN. RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. BMC Bioinformatics. 2011;12:323.
Thorsson V, Gibbs DL, Brown SD, Wolf D, Bortone DS, Ou Yang TH, et al. The immune landscape of cancer. Immunity.. 2019;51:411–2.
Hayward NK, Wilmott JS, Waddell N, Johansson PA, Field MA, Nones K, et al. Whole-genome landscapes of major melanoma subtypes. Nature. 2017;545:175–80.
Katsoulakis E, Yu Y, Apte AP, Leeman JE, Katabi N, Morris L, et al. Radiomic analysis identifies tumor subtypes associated with distinct molecular and microenvironmental factors in head and neck squamous cell carcinoma. Oral Oncol. 2020;110:104877.
Tangella LP, Clark ME, Gray ES. Resistance mechanisms to targeted therapy in BRAF-mutant melanoma—a mini review. Biochim Biophys Acta Gen Subj. 2020;1865:129736.
Attrill GH, Ferguson PM, Palendira U, Long GV, Wilmott JS, Scolyer RA. The tumour immune landscape and its implications in cutaneous melanoma. Pigment Cell Melanoma Res. 2021;34:529–49.
Kennedy LB, Salama AKS. A review of immune-mediated adverse events in melanoma. Oncol Ther. 2019;7:101–20.
Meirson T, Asher N, Bomze D, Markel G. Safety of BRAF+MEK inhibitor combinations: severe adverse event evaluation. Cancers. 2020;12:1650.